3-phosphoinositide dependent protein kinase 1Genealiases: PDK1 · PRO0461
Q-omics provides the consensus-scored PDPK1 profile across patient tissues and cancer cell-line models. PDPK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDPK1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, PDPK1 protein abundance shows 37,887 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where PDPK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDPK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDPK1 survival associations across molecular data types. PDPK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDPK1 RNA expression–survival associations across cancer types. High PDPK1 expression shows favorable associations in KIRC, HNSC, COAD, READ, PAAD and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PDPK1 RNA expression.
This table summarizes PDPK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PDPK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDPK1 shows lower tumor expression in THCA, UCEC and KIRC and higher tumor expression in LIHC, STAD and BRCA. The LIHC box plot shows higher PDPK1 RNA expression in tumor versus normal tissue (log2 FC = +0.979, t-test p < 0.001).
This table shows molecular features associated with PDPK1 in patient tissues and cancer cell lines. In patient samples, PDPK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDPK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
